Tamsulosin for treatment of urinary tract disorder in women

A comparison of the effect of Tamsulosin and placebo in the treatment of urinary tract disorder in women

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200111046086N1

Enrollment

252

Registered

2020-03-31

Start date

2019-08-23

Completion date

Unknown

Last updated

2020-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retention of urine. R33

Interventions

Intervention 1: Intervention group: Tamsulosin capsule with a dose of 0.4 mg made in Iran, one daily for a maximum of 4 weeks. Intervention 2: Control group: placebo capsule made in Iran, one daily fo

Eligibility

Sex/Gender

Female

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Women with at least three months of urinary tract disorder Age between 18 to 65 years old Signing informed consent form

Exclusion criteria

Exclusion criteria: Active urinary tract infection History of neurological disorders Pregnant women

Design outcomes

Primary

Measure	Time frame
Urinary symptoms (urgency; frequency; nocturia; dysuria; incomplete emptying). Timepoint: 1 Weeks after intervention. Method of measurement: Standard questionnaire (USSQ).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSakineh Haj Eebrahimi

Tabriz University of Medical Sciences

hajebrahimis@gmail.com+98 41 3334 7054

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026